Tesamorelin is a synthetic peptide that was specifically developed to help people with HIV who develop a condition where fat accumulates around their midsection and organs, creating health problems and changing their body shape. While it's FDA-approved for this specific use, some people are interested in it because of its unique ability to target the dangerous visceral fat that wraps around your internal organs, rather than the fat you can pinch under your skin.
Think of tesamorelin as a messenger that talks directly to your pituitary gland, the master control center in your brain. When you take it, the peptide binds to specific receptors and essentially tricks your pituitary into releasing more growth hormone, just like it did when you were younger. This growth hormone then acts like a targeted cleanup crew, specifically going after the visceral fat around your organs and breaking it down for energy. What makes tesamorelin special is its precision – it's remarkably selective at reducing this deep, organ-surrounding fat without significantly affecting the fat elsewhere in your body. As this process happens, many people also see improvements in their cholesterol levels and markers of inflammation, creating a ripple effect of metabolic benefits beyond just the fat loss.
Dosage Information
Typical Dose
2 mg
Frequency
Once daily
Administration
Subcutaneous injection
Half-Life
26–38 minutes
Notes
FDA-approved dose is 2mg daily. Clinical trials showed significant visceral fat reduction within 26 weeks. Must be administered on empty stomach.
Why this matters
Short half-life but potent; once-daily injection is standard clinical protocol.
Protocol cycle
Dose Calculator
Calculate your draw amount for an insulin syringe (U-100)
Draw to the
80
unit mark
Draw 80 units for your 2000mcg dose of Tesamorelin
This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.
Where does Tesamorelin sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.35
Compound Data
Molecular Formula
C221H366N72O67S
Molecular Weight
5136.00 g/mol
IUPAC Name
(4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(E)-hex-3-enoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
PubChem CID
16137828Potential Side Effects
Tesamorelin discussions
Stacking Compatibility
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 2 mg
- Frequency
- Once daily
- References
- 2 curated + 0 from PubMed
- Clinical Trials
- 1 registered
- Evidence Score
- 0.3 / 100
Frequently Asked Questions about Tesamorelin
What is Tesamorelin?
Tesamorelin is a synthetic GHRH analog that is FDA-approved for the treatment of HIV-associated lipodystrophy. It is the only GHRH peptide with full FDA approval for a specific medical condition. It is particularly effective at reducing visceral adipose tissue (VAT) without significantly affecting subcutaneous fat.
How does Tesamorelin work?
Tesamorelin stimulates pituitary GH release by binding to GHRH receptors, specifically targeting visceral fat reduction through GH-mediated lipolysis. It has been shown to reduce trunk fat, improve lipid profiles (triglycerides), and decrease C-reactive protein levels. Its selective action on visceral fat distinguishes it from other GH-related peptides.
What is the recommended dosage for Tesamorelin?
The typical dose is 2 mg. Once daily. Administration: Subcutaneous injection. FDA-approved dose is 2mg daily. Clinical trials showed significant visceral fat reduction within 26 weeks. Must be administered on empty stomach.
What are the side effects of Tesamorelin?
Injection site reactions. Joint pain (arthralgia). Peripheral edema. Myalgia. Paresthesia
What is the Tesamorelin cycle protocol?
Tesamorelin is typically cycled continuous. FDA-approved daily maintenance therapy
Questions reflect common community inquiries. This is not medical advice.